Abstract
Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 218-222 |
| Number of pages | 5 |
| Journal | Antiviral Research |
| Volume | 133 |
| DOIs | |
| State | Published - Sep 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Virology
Cite this
Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. / Cross, Robert; Mire, Chad; Branco, Luis M.; Geisbert, Joan B.; Rowland, Megan M.; Heinrich, Megan L.; Goba, Augustine; Momoh, Mambu; Grant, Donald S.; Fullah, Mohamed; Khan, Sheik Humarr; Robinson, James E.; Geisbert, Thomas; Garry, Robert F.
In: Antiviral Research, Vol. 133, 01.09.2016, p. 218-222.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies
AU - Cross, Robert
AU - Mire, Chad
AU - Branco, Luis M.
AU - Geisbert, Joan B.
AU - Rowland, Megan M.
AU - Heinrich, Megan L.
AU - Goba, Augustine
AU - Momoh, Mambu
AU - Grant, Donald S.
AU - Fullah, Mohamed
AU - Khan, Sheik Humarr
AU - Robinson, James E.
AU - Geisbert, Thomas
AU - Garry, Robert F.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
AB - Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
UR - http://www.scopus.com/inward/record.url?scp=84983735536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983735536&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2016.08.012
DO - 10.1016/j.antiviral.2016.08.012
M3 - Article
C2 - 27531367
AN - SCOPUS:84983735536
VL - 133
SP - 218
EP - 222
JO - Antiviral Research
JF - Antiviral Research
SN - 0166-3542
ER -